跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NALOXONE INJECTABLE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NALOXONE INJECTABLE
Authorized
STANDARD
NALOXONE INJECTABLE
hikma canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
01f05a61703fe07d
Company
hikma canada limited
Type
Standard
Approval Details
Approval Id
01f05a61703fe07d
Drug Approval Canada Name
NALOXONE INJECTABLE
Product Name
NALOXONE INJECTABLE
Status
Marketed
Status Date
2022-05-19
Original Market Date
2018-06-12
Din
02458578
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intramuscular , Subcutaneous , Intravenous
Schedule
Ethical
Ahfs
28:10.00
Atc Original
V03AB15 NALOXONE
Atc Name
v 03 ab 15
Aig Number
0108981002
Company Name
hikma canada limited
Company Address
5995 Avebury Road, Suite 804, Mississauga, Ontario, Canada, L5R 3P9
Active Ingredients
NALOXONE HYDROCHLORIDE
0.4 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
01f05a61703fe07d
Type
Standard
Back to Health Canada Approvals